Effect of MCI-9042, a 5-HT2 receptor antagonist, on retinal ganglion cell death and retinal ischemia

Experimental Eye Research

Volumn 76, Issue 4, 2003, Pages 445-452

  Inoue Matsuhisa, Eri ^a   Sogo, Shunji ^b   Mizota, Atsushi ^c   Taniai, Mariko ^c   Takenaka, Hisashi ^b   Mano, Tomiya ^b  

^a c/o Osaka Kasei Corporation ^*  (Japan)

^b Tane Memorial Eye Hospital   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

5 HT2 receptor antagonist; Glaucoma; MCI 9042; Neuroprotection; Retinal ganglion cell death; Retinal ischemia

Indexed keywords

1 ISOPROPYL 6 METHYLERGOLINE 8 CARBOXYLIC ACID 2 HYDROXY 1 METHYLPROPYL ESTER; DRUG METABOLITE; ESTER DERIVATIVE; GLUTAMIC ACID; KETANSERIN; M 1; SARPOGRELATE; SEROTONIN 3 ANTAGONIST; AMINO ACID RECEPTOR BLOCKING AGENT; NEUROPROTECTIVE AGENT; SEROTONIN ANTAGONIST; SUCCINIC ACID DERIVATIVE;

A WAVE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; B WAVE; CELL COUNT; CELL CULTURE; CELL DEATH; CELL ISOLATION; CELL PROLIFERATION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG SCREENING; ELECTRORETINOGRAM; EVALUATION; HISTOLOGY; IN VITRO STUDY; IN VIVO STUDY; INTRAOCULAR PRESSURE ABNORMALITY; MALE; MORPHOMETRICS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; RETINA CELL; RETINA GANGLION CELL; RETINA INJURY; RETINA ISCHEMIA; STAINING; THICKNESS; ANIMAL; DOSE RESPONSE; ELECTRORETINOGRAPHY; INTRAOCULAR HYPERTENSION; REPERFUSION INJURY; RETINA BLOOD VESSEL; WISTAR RAT;

ANIMALS; CELL DEATH; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRORETINOGRAPHY; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMIC ACID; NEUROPROTECTIVE AGENTS; OCULAR HYPERTENSION; RATS; RATS, WISTAR; REPERFUSION INJURY; RETINAL GANGLION CELLS; RETINAL VESSELS; SEROTONIN ANTAGONISTS; SUCCINATES;

EID: 0037375266     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4835(02)00333-0     Document Type: Article

References (48)

1. Akaike A., Adachi K., Kaneda K. Techniques for evaluating neuronal death of the retina in vitro and in vivo. Folia Pharmacol. Jpn. 111:1998;97-104.
2. Bettler B., Mulle C. Review: neurotransmitter receptors. II. AMPA and kainate receptors. Neuropharmacology. 34:1995;123-139.
3. Barres B.A., Silverstein B.E., Corey D.P., Chun L.L. Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron. 1:1988;791-803.
4. Buchi E.R., Suivaizdis I., Fu J. Pressure-induced retinal ischemia in rats: an experimental model for quantitative study. Ophthalmologica. 203:1991;138-147.
5. Carvalho A.L., Duarte C.B., Faro C.J., Carvalho A.P., Pires E.V. Calcium influx through AMPA receptors and through calcium channels is regulated by protein kinase C in cultured retina amacrine-like cells. J. Neurochem. 70:1998;2112-2119.
6. Chang F.W., Burke J.A., Potter D.E. Mechanism of the ocular hypotensive action of ketanserin. J. Ocul. Pharmacol. 1:1985;137-147.
7. Chidlow G., Nash M.S., De Santis L.M. The 5-HT(1A) Receptor agonist 8-OH-DPAT lowers intraocular pressure in normotensive NZW rabbits. Exp. Eye Res. 69:1999;587-593.
8. Costagliola C., Scibelli G., Fasano M.L., Ferrara L.A., Mastropasqua L. Effect of oral ketanserin administration on intraocular pressure in glaucomatous patients. Exp. Eye Res. 52:1991;507-510.
9. Daw M.I., Chittajallu R., Bortolotto Z.A., Dev K.K., Duprat F., Henley J.M., Collingridge G.L., Isaac J.T. PDZ proteins interacting with C-terminal GluR2/3 are involved in a PKC-dependent regulation of AMPA receptors at hippocampal synapses. Neuron. 28:2000;873-886.
10. Dreyer E.B., Zurakowski D., Schumer R.A., Podos S.M., Lipton S.A. Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch. Ophthalmol. 114:1996;299-305.
11. Fujikura H., Kato H., Nakano S., Kogure K. A serotonin S2 antagonist, naftidrofuryl, exhibited a protective effect on ischemic neuronal damage in the gerbil. Brain Res. 494:1989;387-390.
12. 2+ permeability of AMPA receptors in principal neurons and interneurons in rat CNS. Neuron. 15:1995;193-204.
13. 2+ influx in hippocampal CA1 neurons of gerbil. J. Neurosci. 17:1997;6179-6188.
14. Hara H., Osakabe M., Kitajima A., Tamao Y., Kikumoto R. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb. Haemost. 65:1991;415-420.
15. Hara H., Kitajima A., Shimada H., Tamao Y. Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb. Haemost. 66:1991;484-488.
16. Hara H., Shimada H., Kitajima A., Tamao Y. Effect of (+/-)-2- (dimethylamino)-1-[[o-(m-methoxyphenethyl)phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease. Arzneimittelforschung. 41:1991;616-620.
17. Hof P.R., Lee P.Y., Yeung G., Wang R.F., Podos S.M., Morrison J.H. Glutamate receptor subunit GluR2 and NMDAR1 immunoreactivity in the retina of macaque monkeys with experimental glaucoma does not identify vulnerable neurons. Exp. Neurol. 153:1998;234-241.
18. Hollmann M., Heinemann S. Cloned glutamate receptors. Annu. Rev. Neurosci. 17:1994;31-108.
19. Hughes W.F. Quantitation of ischemic damage in the rat retina. Exp. Eye Res. 53:1991;573-582.
20. 2 receptor-mediated phosphoinositide hydrolysis in bovine ciliary epithelium. J. Ocul. Pharmacol. Ther. 2003;. in press.
21. Johansson K., Bruun A., Torngren M., Ehinger B. Development of glutamate receptor subunit 2 immunoreactivity in postnatal rat retina. Vis. Neurosci. 17:2000;737-742.
22. Kato S., Kishiro I., Machida M., Fuse D., Yoshida T., Kaneko N. Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis. J. Int. Med. Res. 28:2000;258-268.
23. Karasawa Y., Araki H., Otomo S. Effects of ketanserin and mianserin on delayed neuronal death induced by cerebral ischemia in Mongolian gerbils. Psychopharmacology (Berl). 109:1992;264-270.
24. Kim C.H., Chung H.J., Lee H.K., Huganir R.L. Interaction of the AMPA receptor subunit GluR2/3 with PDZ domains regulates hippocampal long-term depression. Proc. Nat. Acad. Sci. USA. 98:2001;11725-11730.
25. Klisch J., Bode-Greuel K.M. Ketanserin reduces neuronal calcium accumulation and cell death in the hippocampus of the Mongolian gerbil after transient forebrain ischemia. Brain Res. 578:1992;1-7.
26. Klootila K., Palkama A., Uusitalo H. Effect of serotonin and its antagonist (ketanserin) on intraocular pressure in the rabbit. J. Ocul. Phamacol. 3:1987;279-290.
27. Kumagai S., Morinobu A., Ozaki S., Nakao K., Ishida H. Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases. Ryumachi. 38:1998;504-510.
28. Lagreze W.A., Knorle R., Bach M., Feuerstein T.J. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest. Ophthalmol. Vis. Sci. 39:1998;1063-1066.
29. Lam T.T. The effect of 3-aminobenzamide, an inhibitor of poly-ADP-ribose polymerase, on ischemia/reperfusion damage in rat retina. Res. Commun. Mol. Pathol. Pharmacol. 95:1997;241-252.
30. 2 antagonist, on intraocular pressure in rabbits. Invest. Ophthalmol. Vis. Sci. 36:1995;S719.
31. Meyer-Bothling U., Bron A.J., Osborne N.N. Topical application of serotonin or the 5-HT1 agonist 5-CT: intraocluar pressure in rabbits. Invest. Ophthalmol. Vis. Sci. 34:1993;3035-3042.
32. Meyer-Franke A., Kaplan M.R., Pfrieger F.W., Barres B.A. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron. 15:1995;805-819.
33. Oh S.J., Ha H.J., Chi D.Y., Lee H.K. Serotonin receptor and transporter ligands - current status. Curr. Med. Chem. 8:2001;999-1034.
34. Osborne N.N., Ugarte M., Chao M., Chidlow G., Bae J.H., Wood J.P., Nash M.S. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv. Ophthalmol. 43:1999;S102-S128.
35. Otori Y., Wei J.Y., Barnstable C.J. Neurotoxic effects of low doses of glutamate on purified rat retinal ganglion cells. Invest. Ophthalmol. Vis. Sci. 39:1998;972-981.
36. Pauwels P.J. Diverse signalling by 5-hydroxytryptamine (5-HT) receptors. Biochem. Pharmacol. 60:2000;1743-1750.
37. 2 receptor blocker on blood vessels of the rat. Acta. Physiol. Hung. 84:1996;323-324.
38. 2a receptors in the rabbit retina: potential presynaptic modulators. Vis. Neurosci. 16:1999;221-230.
39. Qin P., Pourcho R.G. AMPA-selective glutamate receptor subunits GluR2 and GluR4 in the cat retina: an immunocytochemical study [published erratum appears in Vis. Neurosci. 17 (2000) 155]. Vis. Neurosci. 16:1999;1105-1114.
40. Sheng M., Lee S.H. AMPA receptor trafficking and the control of synaptic transmission. Cell. 105:2001;825-828.
41. Shutoh F., Hamada S., Narita M., Okado N. Ketanserin modulates GluR2/3 receptor expression in the rat cerebral cortex. Soc. Neurosci. 25:1999;1788.
42. Shutoh F., Hamada S., Okado N. Serotonergic modulation of AMPA receptor in the rat cerebral cortex. Jpn. J. Pharmacol. 82:2000;S231.
43. Shutoh F., Hamada S., Shibata M., Narita M., Shiga T., Azmitia E.C., Okado N. Long term depletion of serotonin leads to selective changes in glutamate receptor subunits. Neurosci. Res. 38:2000;365-371.
44. Sucher N.J., Lipton S.A., Dreyer E.B. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res. 37:1997;3483-3493.
45. 2 antagonist on intraocular pressure in glaucoma patients. Invest. Ophthalmol. Vis. Sci. 36:1995;S734.
46. Tanaka T., Fujita M., Nakae I., Tamaki S., Hasegawa K., Kihara Y., Nohara R., Sasayama S. Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. Am. Coll. Cardiol. 32:1998;1982-1986.
47. Tyan S.H., Sue T.Y., Hon Y.S., Gean P.W., Chang Y.C. A novel NMDA receptor antagonist protects against N-methyl-D-aspartate-and glutamate-induced neurotoxicity in the goldfish retina. Eur. J. Pharmacol. 321:1997;171-179.
48. Zhang S., Kashii S., Yasuyoshi H., Honda Y., Ujihara H., Sasa M., Tamura Y., Akaike A. Involvement of NMDA-receptor in kainate-induced neurotoxicity in cultured fetal retinal neurons. Graefes Arch. Clin. Exp. Ophthalmol. 238:2000;243-248.